Pfizer Animal Health, VMR&D, Ramsgate Road, Sandwich CT13 9NJ, UK.
Vet J. 2011 Mar;187(3):330-4. doi: 10.1016/j.tvjl.2009.12.013. Epub 2010 Jan 13.
Bovine viral diarrhoea virus (BVDV) is one of the most common and economically important viral infections of cattle. As vaccination is common in most European countries, differentiation between infected and vaccinated animals is one of the key challenges facing BVDV eradication campaigns. This study was designed to compare the ability of commercial ELISA kits to differentiate antibodies generated following vaccination with four different commercial inactivated BVDV vaccines from antibodies generated following challenge with virulent BVDV. Although none of the tested vaccine-ELISA combinations was able to differentiate an infected from a vaccinated animal (DIVA) at the individual animal level, p80 blocking ELISAs, in combination with inactivated BVDV vaccines, may have some value under certain circumstances at herd level. In most cases, antibody responses to BVDV vaccines cannot be clearly distinguished from responses seen in the early phase of natural infection. No commercial BVD vaccine showed true marker qualities for DIVA using p80 blocking ELISAs.
牛病毒性腹泻病毒（BVDV）是牛群中最常见和最重要的经济病毒感染之一。由于在大多数欧洲国家都进行了疫苗接种，因此区分感染动物和接种疫苗动物是 BVDV 根除运动面临的关键挑战之一。本研究旨在比较四种不同的商业灭活 BVDV 疫苗接种后产生的抗体与强毒 BVDV 攻毒后产生的抗体的商业 ELISA 试剂盒的区分能力。尽管没有一种检测疫苗 ELISA 组合能够在个体动物水平上区分感染动物和接种疫苗动物（DIVA），但 p80 阻断 ELISA 与灭活 BVDV 疫苗联合使用，在某些情况下可能在群体水平上具有一定价值。在大多数情况下，BVDV 疫苗的抗体反应与自然感染早期所见的反应无法明确区分。没有一种商业 BVD 疫苗使用 p80 阻断 ELISA 表现出真正的 DIVA 标记特性。
